

29th European Multiple Myeloma Academy

January 26-27, 2024 | Vienna, Austria

Program

Friday, January 26, 2024

8.30-8.40 Opening

Heinz Ludwig and Jesús F. San-Miguel

MYELOMA BIOLOGY AND RISK STRATIFICATION

Moderator: Heinz Ludwig

8.40-9.00 The genetic evolution from MGUS to multiple myeloma

Niccolò Bolli

9.00-9.20 The role of the immune environment in the evolution and course of myeloma

Niels Weinhold

9.20-9.40 New risk classification of multiple myeloma

Herve Avet Loiseau

9.40-10.10 Discussion around important questions

- Do genomic patterns predict progression of SMM
- Should MGUS/SMM be classified according genomic patterns
- What can be done to modify the immune environment
- Has the time come for revision of risk factors
- Are epigenetic compounds underused

10.10-10.30 BREAK

NOVEL DEVELOPMENTS IN DISEASE AND RESPONSE ASSESSMENT

Moderator: Jesús San Miguel

10.30-10.50 Diagnostic workup of monoclonal gammopathies

Bruno Paiva

10.50-11.10 Modern imaging for diagnosis and prognostication

Elena Zamagni

11.10-11.30 Response assessment – technical and clinical considerations

Noemi Puig

11.30 -12.00 Discussion around important questions

- Requirements of regulatory agencies for approving MRD
- Circulating plasma cells for disease and response assessment
- Optimizing imaging technologies – MRI and PET/CT
- Impact of higher M-protein detection sensitivity (MGUS and MRD)
- MRD assessment and MGUS-like MM

WORKSHOPS

12.00-12.30 Prevention and treatment of bone disease

Evangelos Terpos

12.00-12.30 Prevention and Management of infections in multiple myeloma

Heinz Ludwig

12.00-12.30 Management of Plasma cell leukemia, extramedullary myeloma and solitary plasmocytoma

Kwee Yong

12.30- 13.30 LUNCH

MANAGEMENT OF PATIENTS WITH SMOLDERING AND TRANSPLANT ELIGIBLE DISEASE

Moderator: Heinz Ludwig

13.30-13.50 The pros and cons for early treatment intervention in smoldering multiple myeloma

Heinz Ludwig

13.50-14.10 Standard and evolving treatment regimens for first line therapy of transplant eligible patients

Philippe Moreau

14:10-14.30 Latest clinical study data impacting on clinical practice

Pieter Sonneveld

14.30-14.50 Maintenance treatment with lenalidomide and beyond

Michele Cavo

14.50-15.20 Discussion around important questions

- Can prediction of early progression in SMM be further improved?
- Upfront ASCT yields longer PFS but similar OS compared to delayed or no ASCT. Does this principle apply to SMM as well?
- What is the optimal number of induction and consolidation cycles?
- MRD guide therapy ready for prime time?
- Maintenance therapy tomorrow?

15.20-15.40 BREAK

MANAGEMENT OF TRANSPLANT INELIGIBLE PATIENTS

Moderator: Jesús San Miguel

15.40-16.00 The impact of frailty and comorbidities on treatment selection

Alessandra Larocca

16.00-16.20 Treatment of TNE patients, today and tomorrow

Thierry Facon

16.20-16.50 Discussion of important questions

- Treatment of very elderly patients
- Myeloma related versus other comorbidities
- Initiation of therapy at biochemical progression
- Treatment duration
- Impact of individual risk on treatment selection

16.50-17.00 BREAK

17.00-17.30 WORKSHOPS (repeated)

KEYNOTE LECTURE

17.30-18.00 Multiple myeloma research and treatment on the move. A look into the future

Jesús San-Miguel

Saturday, January 28, 2023

THE BEST APPROACH TO PATIENTS WITH RELAPSED/REFRACTORY DISEASE

Moderator: Heinz Ludwig

8.30-8.50 Treatment strategies after relapse

Maria-Victoria Mateos

8.50-9.10 How I treat patients with high-risk disease

Mohammad Mothy

9.10-9.30 Indications and efficacy of new drugs in clinical development including Blenrep, Selinexor, Melflufen, Venetoclax and new IMiDs

Evangelos Terpos

9.30-10.00 Discussion of important questions

- Limitations of the definition of refractoriness
- Management of early relapse
- Lenalidomide refractory patients
- CD38 retreatment
- Optimizing therapy in high-risk RRMM patients

10.00-10.20 BREAK

HOT TOPICS IN MYELOMA

Moderator: Jesús San Miguel

10.20- 10.40 Antibody based immunotherapy

Niels van de Donk

10.40 -11.00 CAR-T cells and other cellular therapies

Hermann Einsele

11.00-11.30 Discussion of important questions

- Resistance mechanisms for CD38 antibodies
- Is there an optimal target for BsAbs and CAR-T cells?
- Pros and cons for BsAbs or CAR-T cells
- Impact of CAR-T cell persistence on outcome
- Prevention of toxicities of BsAbs and CAR-T cells

AMYLOIDOSIS AND WADENSTRÖM'S DISEASE

Moderator: Heinz Ludwig

11.30-11.50 Progress in the management of Amyloidosis

Giampaolo Merlini

11.50-12.10 Treatment approaches in Waldenström's disease

Melitos A. Dimopoulos

12.10-12.40 Discussion of important questions

- Is cure a realistic goal in amyloidosis?
- Cellular therapies in amyloidosis
- Treatment of patients failing to first-line treatment with PTK inhibitors and CD20+ based therapies
- Should anti-BCMA treatments be explored in Waldenström's disease as 2/3 express BCMA on their tumor clones?

12.40-12.50 Closure of the meeting

Heinz Ludwig and Jesús San Miguel